Redefining the Position of Hormonal Therapy in Endometrial Cancer in the Era of Molecular Classification

In the setting of advanced and recurrent EC, recent reviews and meta-analyses confirmed a response to progestin treatment of 30% in unselected patients. 23,27,28However, these studies also emphasized that the efficacy of HT is higher in selected subgroups of patients with hormone receptor-positive tumors.In these patient groups, HT can be as effective as chemotherapy, which is especially relevant in patients with advanced and recurrent EC who often ACCOMPANYING CONTENT Appendix